Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis
Status:
Recruiting
Trial end date:
2022-09-12
Target enrollment:
Participant gender:
Summary
Primary Objective:
- Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed
after skin tape stripping (STS) in predefined lesional skin in pediatric patients with
moderate to severe atopic dermatitis (AD) treated with dupilumab
Secondary Objectives:
- Evaluate changes in skin barrier function with TEWL assessed after STS in predefined
lesional and non lesional skin in pediatric patients with moderate to severe AD treated
with dupilumab in reference to normal skin of healthy volunteers.
- Evaluate time course of change in skin barrier function with TEWL assessed before and
after STS in predefined lesional and non-lesional skin in pediatric patients with
moderate to severe AD during dupilumab treatment phase and follow-up period in reference
to normal skin of healthy volunteers